Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel plus Oxaliplatin CCRT in Esophageal Cancer
NCT02607982Phase 2Completed
- Start
- Jan 2005
- Primary completion
- Jun 2014
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection and oxaliplatin in esophageal cancer. Primary endpoint: Response Rate at 4 weeks. Started Jan 2005; status: completed.
02
Drugs
Paclitaxel Micelles for Injectionoxaliplatin
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02607982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607982.